DDInter1592 DDInter1676
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Rifapentine {u} (Compound) resembles {v} (Compound) Rifabutin
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A4
Rifapentine {u} (Compound) upregulates {v} (Gene) DDIT4
Rifapentine {u} (Compound) is included by {v} (Pharmacologic Class) Rifamycins
Rifapentine (Compound) resembles Rifabutin (Compound)
Rifapentine (Compound) resembles Rifaximin (Compound)
Rifapentine (Compound) binds CYP3A4 (Gene)
Rifapentine (Compound) upregulates DDIT4 (Gene)
Rifapentine (Compound) is included by Rifamycins (Pharmacologic Class)